Zealand Pharma applies for FDA approval for blood sugar treatment

Zealand Pharma has sent dasiglucagon, which is a treatment for low blood sugar administered through auto-injector Hypopal, for approval at the FDA.

Photo: Zealand Pharma / PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles